Background/Aim: The determinants of baseline fast solute transport are still unclear. We prospectively investigated the relationship of peritoneal solute transport with markers of inflammation, angiogenesis, and membrane status, with a focus on fast transporters. Methods: Seventy-one incident peritoneal dialysis patients were assessed with baseline and annual peritoneal equilibration tests, using a 3.86% glucose dialysis solution. Residual renal function and markers of inflammation, including systemic and intraperitoneal interleukin-6 (IL-6), effluent cancer antigen 125 (CA-125), and vascular endothelial growth factor (VEGF) appearance rates (ARs), were investigated. The time course of the dialysate-to-plasma ratio of creatinine (D/P creatinine ratio) and its relationship with the biomarkers were investigated by a mixed linear model. Results: Incident fast/fast average transporters had a similar age, diabetes prevalence, and serum and effluent IL-6 levels, but significantly higher levels of CA-125 and VEGF ARs than the slow/slow average group; the D/P creatinine ratio was not correlated with systemic IL-6, but was correlated with effluent CA-125 AR (r = 0.45, p < 0.0001) and VEGF AR (r = 0.52, p < 0.0001). The D/P creatinine ratio decreased with a U-shaped profile (p = 0.02). Intraperitoneal IL-6 was the significant and positive determinant of the time course of the D/P creatinine ratio (p < 0.0001). Effluent CA-125 decreased with time on peritoneal dialysis (p = 0.013). Conclusions: Baseline peritoneal fast transport was not associated with systemic inflammation, but was related to peritoneal locally produced substances able to mediate transitory hyperpermeability. The D/P creatinine ratio changed during the follow-up period with a U-shaped profile. This was associated with effluent IL-6 and partly with VEGF. CA-125 decreased throughout the follow-up period.

Rumpsfeld M, McDonald SP, Purdie DM, Collins J, Johnson DW: Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 2004;43:492–501.
Szeto CC, Law MC, Wong TY, Leung CB, Li PK: Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: a 2-year prospective study. Am J Kidney Dis 2001;37:329–336.
Chung SH, Chu WS, Lee HA, Kim YH, Lee IS, Lindholm B, Lee HB: Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 2000;20:541–547.
Chung SH, Heimburger O, Stenvinkel P, Bergström J, Lindholm B: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001;16:2240–2245.
Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimburger O: Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006;26:53–63.
Krediet RT, Zweers MM, van der Wal AC, Struijk DG: Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000;20(Suppl 2):S19–S25.
Margetts PJ, McMullin JP, Rabbat CG, Churchill DN: Peritoneal membrane transport and hypoalbuminemia: cause or effect? Perit Dial Int 2000;20:14–18.
Rumpsfeld M, McDonald SP, Johnson DW: Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006;17:271–278.
Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG: Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006;17:2591–2598.
Chung SH, Heimburger O, Stenvinkel P, Qureshi AR, Lindholm B: Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003;18:590–597.
Rodrigues AS, Almeida M, Fonseca I, Martins M, Carvalho MJ, Silva F, Correia C, Santos MJ, Cabrita A: Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated to systemic inflammation. Nephrol Dial Transplant 2006;21:763–769.
Van Esch S, Zweers MM, Jansen MA, de Waart DR, van Manen JG, Krediet RT: Determinants of peritoneal solute transport rates in newly started non-diabetic peritoneal dialysis patients. Perit Dial Int 2004;24:554–561.
Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307–1320.
Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent dialysis patients. Perit Dial Int 2003;23:74–83.
Park HC, Kang SW, Choi KH, Ha SK, Han DS, Lee HY: Clinical outcome in continuous ambulatory peritoneal dialysis patients is not influenced by high peritoneal transport status. Perit Dial Int 2001;21(Suppl 3):S80–S85.
Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT: Predictors of poor outcome in chronic dialysis patients: The Netherlands’ Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis 2000;35:69–79.
Rocco MV, Frankenfield DL, Prowant B, Frederick P, Flanigan MJ: Risk factors for early mortality in U.S. peritoneal dialysis patients: impact of residual renal function. Perit Dial Int 2002;22:371–379.
Jager KJ, Merkus MP, Dekker FW, Boeschoten EW, Tijssen JG, Stevens P, Bos WJ, Krediet RT: Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands’ Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int 1999;55:1476–1485.
Krediet RT: Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001;21:560–567.
Ha H, Cha MK, Choi HN, Lee HB: Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002;22:171–177.
Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T: Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002;61:570–578.
Rodrigues AS, Martins M, Santos MJ, Fonseca I, Oliveira JC, Cabrita A, Castro e Melo J, KredietRT: Evaluation of effluent markers CA 125, VEGF and IL-6: relationship with peritoneal transport. Adv Perit Dial 2004;20:8–12.
Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT; Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470–479.
Davies SJ: Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004;66:2437–2445.
del Peso G, Fernandez-Reyes MJ, Hevia C, Bajo MA, Castro MJ, Cirugeda A, Sanchez-Tomero JA, Selgas R: Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant 2005;20:1201–1206.
Davies SJ: Getting to grips with individual variation in membrane function. Perit Dial Int 2005;25:35–37.
Breborowicz A, Breborowicz M, Pyda M, Polubinska A, Oreopoulos D: Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephron Clin Pract 2005;100:c46–c51.
Senger DR: Molecular framework for angiogenesis. A coupled web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol 1996;149:1–7.
Topley N, Jörres A, Luttmann W, Petersen MM, Lang MJ, Thierauch KH, Muller C, Coles GA, Davies M, Williams JD: Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int 1993;43:226–233.
Topley N, Mackenzie R, Jörres A, Coles GA, Davies M, Williams JD: Cytokine networks in continuous ambulatory peritoneal dialysis: interactions of resident cells during inflammation in the peritoneal cavity. Perit Dial Int 1993;13(Suppl 2):S82–S85.
Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romão JE Jr, Marcondes M, De Oliveira AH, Noronha IL: Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002;17:1480–1486.
Johansson AC, Haraldsson B: Physiological properties of the peritoneum in an adult peritoneal dialysis population over a three-year period. Perit Dial Int 2006;26:482–489.
Gillerot G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, Stenvinkel P, Heimburger O, Lindholm B, Nordfors L, Robert A, Devuyst O: Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005;67:2477–2487.
Parikova A, Smit W, Struijk DG, Zweers MM, Krediet RT: The contribution of free water transport and small pore transport to the total fluid removal in peritoneal dialysis. Kidney Int 2005;68:1849–1856.
Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT: Longitudinal follow-up of CA125 in peritoneal effluent. Kindey Int 1997;51:888–893.
Aroeira LS, Aguilera A, Selgas R, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, Bajo MA, del Peso G, Sanchez-Tomero JA, Jimenez-Heffernan JA, Lopez-Cabrera M: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005;46:938–948.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.